Nektar Therapeutics
NASDAQ:NKTR
Nektar Therapeutics
Selling, General & Administrative
Nektar Therapeutics
Selling, General & Administrative Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
Company | Selling, General & Administrative | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
---|---|---|---|---|---|---|
Nektar Therapeutics
NASDAQ:NKTR
|
Selling, General & Administrative
-$76.9m
|
CAGR 3-Years
13%
|
CAGR 5-Years
4%
|
CAGR 10-Years
-7%
|
||
Johnson & Johnson
NYSE:JNJ
|
Selling, General & Administrative
-$22.9B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
||
Bristol-Myers Squibb Co
NYSE:BMY
|
Selling, General & Administrative
-$8B
|
CAGR 3-Years
0%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-5%
|
||
Pfizer Inc
NYSE:PFE
|
Selling, General & Administrative
-$14.8B
|
CAGR 3-Years
-7%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
0%
|
||
Merck & Co Inc
NYSE:MRK
|
Selling, General & Administrative
-$10.7B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-1%
|
CAGR 10-Years
0%
|
||
Eli Lilly and Co
NYSE:LLY
|
Selling, General & Administrative
-$8.1B
|
CAGR 3-Years
-8%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
-2%
|
Nektar Therapeutics
Glance View
Nektar Therapeutics is a research-based biopharmaceutical company which engages in discovering and developing medicines in areas of unmet medical need. The company is headquartered in San Francisco, California and currently employs 740 full-time employees. The firm's research and development pipeline of new investigational drugs includes potential therapies for oncology, immunology and virology. In oncology, it is studying several immuno-oncology (I-O) drug candidates, including bempegaldesleukin, NKTR-255 and NKTR-262. In immunology, it is focused on addressing imbalances in the immune system to restore the body's self-tolerance mechanisms and achieve immune homeostasis. In autoimmune disorders, its IL-2 T-regulatory cell stimulator NKTR-358 is being clinically studied in systemic lupus erythematosus, ulcerative colitis, psoriasis and atopic dermatitis. Its programs in virology area include studying bempegaldesleukin in treating individuals affected with COVID-19, and a preclinical research collaboration with Gilead Sciences Inc. (Gilead) to test the combination of NKTR-255.
See Also
What is Nektar Therapeutics's Selling, General & Administrative?
Selling, General & Administrative
-76.9m
USD
Based on the financial report for Sep 30, 2024, Nektar Therapeutics's Selling, General & Administrative amounts to -76.9m USD.
What is Nektar Therapeutics's Selling, General & Administrative growth rate?
Selling, General & Administrative CAGR 10Y
-7%
Over the last year, the Selling, General & Administrative growth was 6%. The average annual Selling, General & Administrative growth rates for Nektar Therapeutics have been 13% over the past three years , 4% over the past five years , and -7% over the past ten years .